82 recruiting, 65 completed, 43 unknown, 41 not yet recruiting. 117 Phase 2, 48 Phase 1, 36 Not applicable, 21 Phase 3, 7 Phase 4.
Follow Neoplasm, Residual: new trials by email Literature Review of Neoplasm, Residual trials Research Report on Neoplasm, Residual
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | University of Nebraska | 50 | 2026-12-12 | 2026-11-06 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| BLinatumomab and iNKT in Relapsed B-Cell ALL Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 13 | 2026-12-01 | 2026-11-05 |
| Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer Patients Multiparametric Magnetic Resonance Imaging of the Bladder - Urinary Bladder Cancer, NMIBC | Not applicable | Not yet recruiting | University of Lausanne Hospitals | 86 | 2026-12-01 | 2026-11-09 |
| Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients Befotinib, Pemetrexed + Cisplatin /Carboplatin - Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation | Phase 2 | Recruiting | Guangzhou University of Traditional Chinese Medicine | 124 | 2026-11-30 | 2026-11-04 |
| CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia CLL-1-CD70 CAR-T Cell Injection - Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-11-30 | 2026-10-27 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-17 | 2026-11-12 |
| MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC Aumolertinib, Pemetrexed, Carboplatin - Non-Small Cell Lung Cancer | Not applicable | Not yet recruiting | Peking University People's Hospital | 50 | 2026-11-01 | 2026-10-14 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy INCA33890 - CRC (Colorectal Cancer) | Phase 2 | Not yet recruiting | Incyte Corporation | 40 | 2026-10-26 | 2026-09-22 |
| Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT NGS-MRD AML cohort - Measurable Residual Disease, Acute Myeloid Leukemia | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 169 | 2026-10-19 | 2026-11-05 | |
| CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-10-15 | 2026-10-26 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | 228 | 2026-10-01 | 2026-08-06 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia SL1CC Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-10-01 | 2026-10-02 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA Patient-specific tumor-informed MRD assay (plasma and bronchial washing ctDNA), Bronchoscopy with bronchial washing for reserach - Non-Small Cell Lung Cancer, Minimal Residual Disease | Recruiting | Eun Hye Lee | 40 | 2026-09-28 | 2026-11-12 | |
| ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing - Colon Cancer, Deficient Mismatch Repair | Phase 2 | Recruiting | Fudan University | 23 | 2026-09-14 | 2026-09-25 |
Showing 20 of 293. Sign in to see all of them.
Leukemia, Myeloid, Acute (48) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (47) · Multiple Myeloma (29) · Breast Neoplasms (21) · Recurrence (19) · Carcinoma, Non-Small-Cell Lung (16) · Colorectal Neoplasms (15) · Leukemia (13) · Burkitt Lymphoma (12) · Myelodysplastic Syndromes (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma (10) · Neoplasms (10) · Colonic Neoplasms (9)
Pathologic Processes (293) · Pathological Conditions, Signs and Symptoms (293) · Neoplastic Processes (292) · Neoplasms (283) · Neoplasms by Histologic Type (178) · Hemic and Lymphatic Diseases (153) · Hematologic Diseases (132) · Immune System Diseases (107) · Immunoproliferative Disorders (104) · Lymphoproliferative Disorders (103) · Neoplasms by Site (100) · Leukemia (95) · Lymphatic Diseases (81) · Leukemia, Lymphoid (56) · Leukemia, Myeloid (53)
Cyclophosphamide (23) · blinatumomab (18) · Cytarabine (16) · Azacitidine (13) · fludarabine (13) · venetoclax (11) · Dexamethasone (10) · Lenalidomide (10) · fludarabine phosphate (10) · Blood Specimen Collection (9) · Rituximab (8) · Daunorubicin (7) · Methotrexate (7) · daratumumab (7) · Carboplatin (6)
Peking University People's Hospital (15) · Institute of Hematology & Blood Diseases Hospital, China (11) · M.D. Anderson Cancer Center (10) · Nanfang Hospital, Southern Medical University (7) · National Cancer Institute (NCI) (6) · Assistance Publique - Hôpitaux de Paris (5) · Novartis Pharmaceuticals (5) · Goethe University (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · PETHEMA Foundation (4) · UNC Lineberger Comprehensive Cancer Center (4) · University Hospital, Montpellier (4) · Amgen (3) · First Affiliated Hospital of Zhejiang University (3) · Fudan University (3)
United States (86) · China (78) · France (31) · Germany (23) · Italy (21) · Spain (19) · Belgium (10) · South Korea (8) · United Kingdom (8) · Canada (7) · Netherlands (7) · Poland (6) · Sweden (6) · Australia (5) · Austria (5)
Qifa Liu (4) · Antonio Curti (2) · David S Schrump, M.D. (2) · Dieter Hoelzer, MD,PhD (2) · Lillian Siu, MD (2) · Nicola Goekbuget, MD (2) · Robert J Kreitman, M.D. (2) · Yara Abdou, MD (2)
PMID 41671463, PMID 19141862, PMID 22442346, PMID 26308596, PMID 26311728, PMID 27209293, PMID 28445469, PMID 29358182, PMID 32619115, PMID 10197236, PMID 10636102, PMID 11215292, PMID 12522257, PMID 12547409, PMID 12949711, PMID 14515284, PMID 14710949, PMID 15654796, PMID 16195338, PMID 18076015, PMID 18670422, PMID 19144982, PMID 20087581, PMID 20388201, PMID 20606084, PMID 21719599, PMID 22058217, PMID 22493293, PMID 22592608, PMID 22851565, PMID 23024237, PMID 2350571, PMID 24128322, PMID 25192414, PMID 25444714, PMID 25450201, PMID 25722745, PMID 25749825, PMID 25966987, PMID 25987569, PMID 25999452, PMID 26154128, PMID 26622800, PMID 26778538, PMID 26863635, PMID 26883583, PMID 27194814, PMID 27216216, PMID 27384348, PMID 27511158
2023 (4), 2017 (3), 2015 (2), 2019 (2), 2025 (2), P30CA015704 (2), P30CA016672 (2), 2014 (1), 2018 (1), K12HL087165 (1), P30CA014599 (1), P30CA072720 (1), R01CA290013 (1), R03CA286676 (1), R03DE030550 (1)